Fundraising Fox
Arctic Fox AI
Techstars '18Montréal, CA · 4 employees on LinkedIn · 1 known investors
Find your way into Arctic Fox AI
Sign up to see every warm intro you have to Arctic Fox AI
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Arctic Fox AI team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AFX Medical develops artificial intelligence software for cancer treatment management and clinical decision support integrated into medical devices for healthcare providers. The company serves oncology clinics and hospitals seeking to improve patient outcomes through AI-augmented diagnostic and treatment tools.
Also known as AFX Medical
Investors · 1
How we know: the Techstars portfolio · funding news · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · Not right? Tell us
Company profile
researched Sep 2026Arctic Fox AI, which operates under the brand AFX Medical, develops software for identifying and tracking brain metastases in neuro-oncology. Its product, AFX-BM, is intended to assist radiologists and radiation oncologists within their existing clinical workflow and integrates with PACS infrastructure. The software suggests the location of potential brain metastases on contrast-enhanced T1 brain MRI images and automatically derives largest bidirectional diameters from the generated segmentation.
Individual findings are listed with their measurements for navigation, and once a finding is approved it receives a unique lesion label that persists across studies. Approved findings corresponding to the same lesion are automatically associated between studies, enabling longitudinal tracking of individual lesions and supporting estimation of clinical endpoints such as RECIST or RANO-BM. The system produces a PDF report summarizing longitudinal data, including tables of tracked findings and graphical displays of lesion size progression. Company materials frame the problem in terms of the volume of imaging review involved: approximately one third of the 17 million new cancer patients per year develop brain metastases, two to ten follow-up brain MRIs are required to monitor treatment response and identify relapses, and more than 1,000 images are reviewed per MRI session.
Business model
The company supplies software tools to healthcare providers, delivered as an application that integrates with existing PACS imaging infrastructure. One company profile classifies its revenue as recurring software sold to enterprise customers.
Traction
The company reported five employees as of February 2024 and maintains a partners section and a research publication record on its website.
Latest developments
The company's website, carrying a 2025 copyright, presents AFX-BM as available to try, with detection and measurement, lesion identification, longitudinal tracking and automated reporting features.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned in AI-based radiology software for neuro-oncology; profiles list RAD AI, Avalon AI, ChestAi and MedCognetics among similar companies.
Technology
AFX-BM applies machine learning to contrast-enhanced T1-weighted brain MRI to segment and measure candidate brain metastases, derive bidirectional diameters, assign persistent lesion labels, and associate lesions across sequential studies for longitudinal tracking and clinical endpoint estimation (RECIST, RANO-BM). Associated research output covers convolutional neural network detection of brain metastases, including volume-aware loss functions and sampling strategies aimed at reducing missed small lesions, and evaluation of deep learning in radiosurgery quality assurance.
Go-to-market
Radiologists, radiation oncologists, clinicians and healthcare providers managing brain tumours and other brain diseases.
Geography
Headquartered at 400 rue Montfort in Montreal, Quebec, Canada.
History
The company was founded in 2018 and participated in the first cohort of the Techstars Montreal AI accelerator, which launched in early 2018 with ten companies. It has since developed and published research on convolutional neural network detection of brain metastases (2022) and on deep learning for radiosurgery quality assurance (2022), and markets the AFX-BM product for brain metastasis detection and tracking.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsPublication reporting that a multi-tier radiosurgery workflow left 0.8% of brain metastases unidentified, and that the AI algorithm detected two additional lesions requiring further treatment.
Publication on automated detection of brain metastases on T1-weighted MRI using a convolutional neural network, examining the impact of volume-aware loss and sampling strategy on the sensitivity/precision trade-off for small lesions.
Arctic Fox AI was among the 10 companies in the first cohort of the Montreal-based, AI-focused Techstars accelerator, which was initiated in early 2018.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- Arctic Fox AIafxmedical.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Arctic Fox AI do?
- Montreal-based developer of AI radiology software that detects and longitudinally tracks brain metastases on MRI.
- Who are Arctic Fox AI's investors?
- Arctic Fox AI's investors include Techstars.
- Where is Arctic Fox AI headquartered?
- Arctic Fox AI is headquartered in Montréal, CA.